Intellia Therapeutics, Inc. 8-K

What Happened
Intellia Therapeutics, Inc. (NTLA) filed a Form 8‑K on June 10, 2026 reporting the results of its June 9, 2026 Annual Meeting. Stockholders elected three Class I directors—Muna Bhanji, R.Ph., Brian Goff, and Jesse Goodman, M.D., M.P.H.—each for three‑year terms through the 2029 annual meeting. Shareholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year 2026, and approved the company’s named executive officer compensation on a non‑binding advisory (“say‑on‑pay”) basis. The filing was signed by CEO John M. Leonard.

Key Details

• Director elections (votes recorded; 30,124,178 non‑votes on director items):
  • Muna Bhanji: For 57,065,465 | Against 1,610,941 | Abstain 62,082
  • Brian Goff: For 46,090,644 | Against 12,582,130 | Abstain 65,714
  • Jesse Goodman: For 43,004,221 | Against 15,686,289 | Abstain 47,978
• Auditor ratification: Deloitte & Touche LLP ratified with For 87,833,534 | Against 779,540 | Abstain 249,592.
• Advisory approval of executive compensation: For 44,806,637 | Against 13,821,404 | Abstain 110,447 (30,124,178 non‑votes).

Why It Matters
These results confirm Intellia’s board composition and governance matters for the coming year and secure Deloitte as the company’s auditor for FY2026. The advisory pay vote passed by a clear margin but attracted meaningful opposition (over 13.8 million “Against” votes), which investors often watch as an indicator of shareholder sentiment on executive pay. The large number of non‑votes reported on director and advisory items (30,124,178) reflects shares that were not cast on those proposals and may affect vote turnout metrics used by investors assessing governance engagement.